CG Oncology director sells 1,000 shares in plan
CG Oncology director Leonard E. Post exercised options for 1,000 shares and sold 1,000 shares the same day under a pre-arranged Rule 10b5-1 trading plan.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
CG Oncology, Inc. (CGON) director Leonard E. Post reported an option exercise-and-sale sequence on September 15, 2026. He exercised options to acquire 1,000 shares of common stock at $0.60 per share and sold 1,000 shares of common stock at a weighted average price of $72.98 under a Rule 10b5-1 trading plan adopted on March 5, 2026. Following the option exercise, he held 103,077 option-based rights directly.
Insider Trade Summary 10b5-1
Exercise and Sale: 1,000 shares ($72K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
POST LEONARD E
Role
Director
Sold
1,000 shs ($73K)
Approx. gross sale proceeds
$73K
Approx. exercise cost
$600.00
Approx. pre-tax spread
$72K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Director Stock Option (right to buy) F3 | 1,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 1,000 | $0.60 | $600.00 |
| Sale | Common Stock F1, F2 | 1,000 | $72.98 | $73K |
Holdings After Transaction:
Director Stock Option (right to buy) — 103,077 contracts (Direct);
Common Stock — 0 shares (Direct)
Footnotes (3)
- F1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.54 to $73.52 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3. Fully vested
Key Figures
Options exercised: 1,000 rights
Option exercise price: $0.60 per share
Shares sold: 1,000 shares
+4 more
7 metrics
Options exercised
1,000 rights
Option-based rights for CG Oncology common stock exercised on September 15, 2026
Option exercise price
$0.60 per share
Exercise price for 1,000 option-based rights on September 15, 2026
Shares sold
1,000 shares
CG Oncology common shares sold on September 15, 2026
Weighted average sale price
$72.98 per share
Weighted average price for 1,000 CG Oncology shares sold on September 15, 2026
Sale price range
$72.54–$73.52 per share
Range of prices for the multiple sale transactions on September 15, 2026
Option-based rights held after exercise
103,077 rights
Director stock option rights held directly by Leonard E. Post after the reported exercise
Rule 10b5-1 plan adoption date
March 5, 2026
Date Leonard E. Post adopted the Rule 10b5-1 trading plan governing the reported sales
Key Terms
Rule 10b5-1 trading plan, weighted average price, Director Stock Option, Common Stock
4 terms
Rule 10b5-1 trading plan regulatory
"The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Director Stock Option financial
"Director Stock Option (right to buy)"
Common Stock financial
"underlying security title Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did CGON director Leonard E. Post report on September 15, 2026?
Leonard E. Post reported exercising options for 1,000 shares of CG Oncology common stock at $0.60 per share and selling 1,000 shares of common stock at a weighted average price of $72.98 on September 15, 2026.
How many CGON options did Leonard E. Post exercise and at what price?
Leonard E. Post exercised 1,000 option-based rights relating to CG Oncology common stock on September 15, 2026 at an exercise price of $0.60 per share, receiving 1,000 shares of common stock upon exercise.
How many CGON option-based rights did Leonard E. Post hold after the reported exercise?
After exercising 1,000 option-based rights on September 15, 2026, Leonard E. Post directly held 103,077 option-based rights related to CG Oncology common stock, as reported in the filing.
What type of securities were involved in Leonard E. Post’s CGON Form 4 filing?
The Form 4 reports transactions in Director Stock Options (rights to buy common stock) and in Common Stock of CG Oncology, Inc., covering both an option exercise and a same-day sale of the resulting shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
